New Pharma partnership to tackle PD - Cure Parkinson's
New Pharma partnership to tackle PD
Only available to registered users.
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK (LSE: GSK) to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication.
The deal marks GSK's second major foray into neurodegenerative diseases in recent years, following its $2.2 billion accord with Alector in 2021 to develop immuno-neurology candidates.
Flagship Pioneering-backed Vesalius will leverage its platform to identify novel intervention points in Parkinson's disease and one additional indication in neurodegeneration, and GSK will have the option to advance programs against those novel intervention points. GSK will also gain worldwide development and commercial rights from Vesalius to a pre-clinical small molecule program with an initial focus in Parkinson's disease.
new pd treatment
New PD owner
New PD Gloves
The Journey and Partnership
New Symptom of PD
